Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal serous cancer
• * Stage IIIB, IIIC, or IV
• * Surgically staged and debulked
• Complete clinical response after first-line platinum-based chemotherapy (cisplatin or carboplatin) defined by all of the following criteria:
• * No evidence of cancer by history or physical examination
• * CA 125 no greater than 35 units/mL
• * No evidence of residual cancer on CT scan of the abdomen/pelvis and chest x-ray
• Must have received at least 5 courses of first-line chemotherapy
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Granulocyte count at least 1,200/mm\^3
• Platelet count at least 90,000/mm\^3
• Hepatic
• Bilirubin normal
• ALT and AST less than 1.5 times upper limit of normal (ULN)
• Alkaline phosphatase less than 1.5 ULN
• Renal
• Creatinine clearance at least 60 mL/min
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent immunotherapy
• Chemotherapy
• See Disease Characteristics
• At least 3 weeks since prior first-line chemotherapy
• At least 3 years since other prior chemotherapy (other than first-line chemotherapy for ovarian, fallopian tube, or primary peritoneal cancer)
• No other concurrent chemotherapy
• Endocrine therapy
• No concurrent hormonal therapy
• Radiotherapy
• No prior abdominopelvic radiotherapy
• No concurrent radiotherapy
• Surgery
• See Disease Characteristics
• No concurrent surgery
• Other
• No other concurrent antitumor therapy